Omnicell, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2022. Financial statements are unaudited; amounts below are in U.S. dollars unless noted.
Business context
Omnicell provides medication-management automation, software, consumables, and services to healthcare systems and pharmacies. It reports as one operating segment. Management’s strategy centers on an integrated, cloud-enabled “Autonomous Pharmacy” platform. Recent acquisitions expanded retail-pharmacy software and specialty-pharmacy services; the January 2022 Hub and Spoke Innovations acquisition cost approximately $3.4 million.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $331.4 million | $272.7 million | $650.2 million | $524.6 million |
| Gross profit | $158.1 million | $136.3 million | $308.1 million | $258.6 million |
| Gross margin | 47.7% | 50.0% | 47.4% | 49.3% |
| Operating income | $12.5 million | $28.9 million | $17.6 million | $48.5 million |
| Net income | $9.1 million | $20.4 million | $17.3 million | $34.6 million |
| Diluted EPS | $0.20 | $0.43 | $0.37 | $0.74 |
| Operating cash flow | Not separately provided for the quarter | Not separately provided for the quarter | $(25.5) million | $129.2 million |
Q2 revenue increased 22% year over year; product revenue rose 19% and services and other revenue 29%. Connected devices, software licenses, and other revenue grew to $215.6 million from $179.0 million. SaaS, subscription software, and technology-enabled services revenue increased to $44.3 million from $23.9 million. Six-month revenue increased 24%.
Despite higher sales, Q2 gross margin declined to 47.7% from 50.0%; operating expenses rose 36% to $145.6 million. The resulting operating income fell 57% and net income fell 56% year over year. For the first half, operating income fell 64% and net income fell 50%. Management cited inflation-related inventory costs, investment in services, revenue mix, lower 340B revenue, increased headcount, and acquisition-related expenses among the factors affecting costs.
At June 30, cash and cash equivalents were $245.0 million, down from $349.1 million at year-end; cash, cash equivalents, and restricted cash totaled $268.8 million. Working capital was $414.3 million, and the current ratio was 2.1, compared with a year-end working-capital deficit of $95.5 million and current ratio of 0.9, primarily because convertible notes had been classified as current at year-end.
Six-month investing cash outflow was $25.6 million, including $21.1 million of capital expenditures and $6.5 million for externally marketed software development, partly offset by acquisition-related working-capital adjustments. Financing cash outflow was $33.6 million, including $52.2 million of share repurchases. Accounts receivable and unbilled receivables increased $71.4 million and inventory increased $32.6 million, contributing to operating cash outflow.
Convertible senior notes had $575.0 million principal and $565.0 million carrying value, net of issuance costs, and mature in September 2025 with a 0.25% coupon. Their reported fair value was $731.7 million. The $500 million revolving credit facility had no borrowings outstanding, and the company reported compliance with its covenants.
Material changes versus comparable periods
- Revenue grew substantially, led by automated dispensing systems and IV solutions, and by acquired businesses and growth in the installed base and services.
- Profitability weakened: gross margin contracted, operating expenses increased faster than revenue, and net income and diluted EPS declined.
- Operating cash flow shifted from $129.2 million provided in the first half of 2021 to $25.5 million used in the first half of 2022, largely reflecting working-capital outflows, including higher receivables and inventory.
- Adoption of accounting guidance for convertible debt on January 1, 2022 reclassified the notes as a single liability and eliminated amortization of the prior debt discount. The adoption changed balance-sheet presentation and interest expense, but had no adoption-date impact on cash flows or the income statement. It also changed diluted-EPS accounting.
- The company repurchased approximately 389,300 shares for $52.2 million during the first half; none were repurchased in Q2.
Outlook, commentary, and risks
- Management said ransomware-related implementation delays made Q2 revenue slightly below expectations; affected customer implementations were expected to occur in the second half of 2022. The filing provides no clear numerical full-year revenue or earnings guidance.
- The May 4 ransomware incident affected internal IT systems. Omnicell said it had contained the incident and restored substantially all critical systems. It recorded $12.5 million of related expenses, partly offset by $11.1 million of expected insurance recoveries; the income statement reflected net expenses of $1.4 million. Delayed invoicing affected collections and free cash flow. The company reported breach notification to fewer than 350 individuals in a related August 2022 disclosure.
- Management believed existing cash, expected operating cash flows, employee-equity proceeds, and available credit would meet needs for at least the next 12 months. It also cited working capital, capital expenditures, acquisitions, contractual obligations, and potential repurchases as expected uses of cash.
- Risks include supply-chain and component availability constraints, inflation, installation timing and capacity, foreign-exchange movements, COVID-19 uncertainty, privacy and cybersecurity exposure, healthcare regulation, and uncertainty around 340B program rules and manufacturer restrictions. Management attributed lower 340B solutions revenue partly to reduced provider utilization following drug-manufacturer actions.
- Non-cancelable purchase commitments were $226.5 million, of which $175.8 million were expected to be paid during the remainder of 2022. The company recorded $5.1 million of first-half lease-asset impairment and abandonment charges related to facility optimization, plus $3.5 million of restructuring costs.
- A biometric-privacy class action had a settlement preliminarily approved, subject to final approval. A separate trade-secrets action brought by Becton, Dickinson and Company was dismissed with prejudice in May 2022 after settlement. The company reported no material legal accrual for the described proceedings.
Important facts for investors to verify
- Whether delayed implementations occurred as expected in the second half, and whether ransomware-related insurance recoveries were realized.
- Whether revenue growth translates into margin recovery, given higher operating costs, inflation, and service-revenue mix.
- Whether receivables and inventory convert to cash and operating cash flow improves after the first-half outflow.
- The conversion conditions and potential dilution or cash requirements associated with the $575 million notes, as well as any changes in credit-facility availability or covenant compliance.
- Developments in cybersecurity, privacy compliance, 340B program rules, and the pending biometric-privacy settlement approval.